Journal of Clinical and Translational Endocrinology最新文献

{"title":"Effects of Lacticaseibacillus rhamnosus HA-114 probiotic supplementation on circulating IGFBP-2 levels during a calorie-restricted diet in overweight humans","authors":"Justine Faramia ,&nbsp;Béatrice S.-Y. Choi ,&nbsp;Lucie Brunelle ,&nbsp;André Marette ,&nbsp;Vicky Drapeau ,&nbsp;Angelo Tremblay ,&nbsp;Frédéric Picard","doi":"10.1016/j.jcte.2024.100357","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100357","url":null,"abstract":"<div><h3>Background and aim</h3><p>Gut microbiota influences energy homeostasis in part through circulating hormones. Insulin-like growth factor-binding protein (IGFBP)-2 is a biomarker whose increase in systemic circulation is associated with positive effects on body weight and metabolism. In a recent clinical trial, probiotic <em>Lacticaseibacillus rhamnosus</em> HA-114 supplementation showed positive effects on eating behaviors and insulin resistance in overweight participants undergoing a weight-loss intervention. In this context, this ancillary study aimed at assessing the impact of <em>L. rhamnosus</em> HA-114 supplementation on plasma IGFBP-2 levels in these individuals, and whether this modulation correlated with changes in fat mass, energy metabolism, and eating behaviors.</p></div><div><h3>Methods</h3><p>Fasting plasma IGFBP-2 concentrations were quantified in 100 overweight or obese men and women enrolled in a 12-week diet-based weight reduction program (−500 kcal/day), in combination with probiotic <em>L. rhamnosus HA-114</em> or placebo supplementation. Baseline and changes in circulating IGFBP-2 concentrations were correlated with anthropometric parameter, glucose and lipid metabolism, cardiorespiratory function and eating behaviors.</p></div><div><h3>Results</h3><p>On average, the intervention reduced BMI by 4.6 % and increased IGFBP-2 by 13 %, regardless of supplementation group. Individuals who presented an increase in IGFBP-2 levels had significantly greater reductions in BMI. Changes in IGFBP-2 levels were correlated with loss in fat mass (r = 0.2, p &lt; 0.001) in the probiotic-supplemented group, but not with other metabolic parameters or eating behaviors. Baseline IGFBP-2 levels were not associated with weight loss or improvements in cardiometabolic parameters.</p></div><div><h3>Conclusion</h3><p>Probiotic supplementation with <em>L. rhamnosus HA-114</em> did not modulate plasma IGFBP-2 levels. Changes in IGFBP-2 levels were correlated with greater reductions in BMI, but not with other metabolic parameters or eating behaviors, indicating that the benefits of HA-114 on eating behaviors are likely independent of IGFBP-2. Additional changes in microbiota might be required to modulate IGFBP-2 and observe its associations with eating behaviors and cardiometabolic improvements.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100357"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000280/pdfft?md5=acba2e712718f8ea3478dca43e01b150&pid=1-s2.0-S2214623724000280-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141329038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and prescribing recommendations for verapamil in newly diagnosed pediatric type 1 diabetes (T1D): The CLVer experience","authors":"Laya Ekhlaspour ,&nbsp;Bruce Buckingham ,&nbsp;Colleen Bauza ,&nbsp;Mark Clements ,&nbsp;Gregory P. Forlenza ,&nbsp;Anna Neyman ,&nbsp;Lisa Norlander ,&nbsp;Marcus Schamberger ,&nbsp;Jennifer L. Sherr ,&nbsp;Ryan Bailey ,&nbsp;Roy W. Beck ,&nbsp;Craig Kollman ,&nbsp;Shannon Beasley ,&nbsp;Erin Cobry ,&nbsp;Linda A. DiMeglio ,&nbsp;Emily Paprocki ,&nbsp;Michelle Van Name ,&nbsp;Antoinette Moran ,&nbsp;for the CLVer Study Group","doi":"10.1016/j.jcte.2024.100352","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100352","url":null,"abstract":"<div><h3>Objectives</h3><p>To report the safety and side effects associated with taking verapamil for beta-cell preservation in children with newly-diagnosed T1D.</p></div><div><h3>Research Design and Methods</h3><p>Eighty-eight participants aged 8.5 to 17.9 years weighing ≥ 30 kg were randomly assigned to verapamil (N = 47) or placebo (N = 41) within 31 days of T1D diagnosis and followed for 12 months from diagnosis, main CLVer study. Drug dosing was weight-based with incremental increases to full dosage. Side effect monitoring included serial measurements of pulse, blood pressure, liver enzymes, and electrocardiograms (ECGs). At study end, participants were enrolled in an observational extension study (CLVerEx), which is ongoing. No study drug is provided during the extension, but participants may use verapamil if prescribed by their diabetes care team.</p></div><div><h3>Results</h3><p>Overall rates of adverse events were low and comparable between verapamil and placebo groups. There was no difference in the frequency of liver function abnormalities. Three CLVer participants reduced or discontinued medication due to asymptomatic ECG changes. One CLVerEx participant (18 years old), treated with placebo during CLVer, who had not had a monitoring ECG, experienced complete AV block with a severe hypotensive episode 6 weeks after reaching his maximum verapamil dose following an inadvertent double dose on the day of the event.</p></div><div><h3>Conclusions</h3><p>The use of verapamil in youth newly-diagnosed with T1D appears generally safe and well tolerated with appropriate monitoring. We strongly recommend monitoring for potential side effects including an ECG at screening and an additional ECG once full dosage is reached.</p><p>ClinicalTrials.gov number: NCT04233034.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100352"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000231/pdfft?md5=10ea6d43da09c7d917395ad3e10ac462&pid=1-s2.0-S2214623724000231-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of gender-affirming hormone therapy duration and body mass index on bone mineral density in gender diverse adults","authors":"Sean J. Iwamoto ,&nbsp;John D. Rice ,&nbsp;Kerrie L. Moreau ,&nbsp;Marc-André Cornier ,&nbsp;Margaret E. Wierman ,&nbsp;Mary P. Mancuso ,&nbsp;Amanuail Gebregzabheir ,&nbsp;Daniel B. Hammond ,&nbsp;Micol S. Rothman","doi":"10.1016/j.jcte.2024.100348","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100348","url":null,"abstract":"<div><h3>Introduction</h3><p>Feminizing and masculinizing gender-affirming hormone therapy (fGAHT, mGAHT) results in bone mineral density (BMD) maintenance or improvement over time in transgender and gender diverse (TGD) adults. Mostly European TGD studies have explored GAHT’s impact on BMD, but the association of BMI and BMD in TGD adults deserves further study.</p></div><div><h3>Objective</h3><p>To determine whether GAHT duration or BMI are associated with BMD and Z-scores among TGD young adults.</p></div><div><h3>Methods</h3><p>Cross-sectional study of nonsmoking TGD adults aged 18–40 years without prior gonadectomy or gonadotropin-releasing hormone agonist (GnRHa) therapy taking GAHT for &gt; 1 year. BMD and Z-scores were collected from dual-energy x-ray absorptiometry. Associations between femoral neck, total hip, and lumbar spine BMDs and Z-scores and the predictors, GAHT duration and BMI, were estimated using linear regression.</p></div><div><h3>Results</h3><p>Among 15 fGAHT and 15 mGAHT, mean BMIs were 27.6 +/- standard deviation (SD) 6.4 kg/m² and 25.3 +/- 5.9 kg/m², respectively. Both groups had mean BMDs and Z-scores within expected male and female reference ranges at all three sites. Higher BMI among mGAHT was associated with higher femoral neck and total hip BMDs (femoral neck: β = 0.019 +/- standard error [SE] 0.007 g/cm², total hip: β = 0.017 +/- 0.006 g/cm²; both p &lt; 0.05) and Z-scores using male and female references. GAHT duration was not associated with BMDs or Z-scores for either group.</p></div><div><h3>Conclusions</h3><p>Z-scores in young, nonsmoking TGD adults taking GAHT for &gt; 1 year, without prior gonadectomy or GnRHa, and with mean BMIs in the overweight range, were reassuringly within the expected ranges for age based on male and female references. Higher BMI, but not longer GAHT duration, was associated with higher femoral neck and total hip BMDs and Z-scores among mGAHT. Larger, prospective studies are needed to understand how body composition changes, normal or low BMIs, and gonadectomy affect bone density in TGD adults.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100348"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221462372400019X/pdfft?md5=9da660886ea8d958e187bf2fab569fd2&pid=1-s2.0-S221462372400019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140842788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory benefits of semaglutide: State of the art","authors":"Habib Yaribeygi ,&nbsp;Mina Maleki ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jcte.2024.100340","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100340","url":null,"abstract":"<div><p>Individuals with diabetes often have chronic inflammation and high levels of inflammatory cytokines, leading to insulin resistance and complications. Anti-inflammatory agents are proposed to prevent these issues, including using antidiabetic medications with anti-inflammatory properties like semaglutide, a GLP-1 analogue. Semaglutide not only lowers glucose but also shows potential anti-inflammatory effects. Studies suggest it can modulate inflammatory responses and benefit those with diabetes. However, the exact mechanisms of its anti-inflammatory effects are not fully understood. This review aims to discuss the latest findings on semaglutide's anti-inflammatory effects and the potential pathways involved.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100340"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000115/pdfft?md5=314c8acf016d37fe0cc568a3018202bd&pid=1-s2.0-S2214623724000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140321117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis","authors":"Bennett Gosiker ,&nbsp;Jude Moutchia ,&nbsp;Nghiem Nguyen ,&nbsp;Darios Getahun ,&nbsp;Michael Goodman","doi":"10.1016/j.jcte.2024.100349","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100349","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of this study was to conduct a systematic review and meta-analysis of changes in low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol, and triglycerides following initiation of feminizing or masculinizing gender affirming hormone therapy (GAHT).</p></div><div><h3>Methods</h3><p>A search of Ovid MEDLINE, Embase, Web of Science, SCOPUS, and CINAHL databases identified potentially relevant articles published from 1990 through 2024. Both observational and randomized trials of adults receiving feminizing or masculinizing GAHT with baseline and follow-up measures were included. Articles were reviewed for eligibility using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines. The risk of bias in each study was quantified using the NHLBI Study Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group. Random effects models were used to compute the before-and-after meta-differences in mean values for each parameter along with the I² statistic to assess heterogeneity of results.</p></div><div><h3>Results</h3><p>Thirty-five studies met the criteria for inclusion in the meta-analysis. Masculinizing GAHT was associated with significant changes in serum lipids from baseline up through the 60-month timepoint with meta-difference of means (95% CI) estimates of 26.2mg/dL (23.3,29.0) for LDL-C, 26.1mg/dL (22.8,29.4) for total cholesterol, 30.7mg/dL (6.9,54.6) for triglycerides and –9.4mg/dL (–12.1, –6.7) for HDL-C. Studies evaluating the effects of feminizing GAHT on balance demonstrated no notable changes in HDL-C or triglycerides while the results for LDL-C and total cholesterol were inconsistent. Heterogeneity of results ranged from minimal (I² = 0%) to substantial (I² = 90%).</p></div><div><h3>Conclusions</h3><p>While the results for transfeminine individuals on GAHT appear somewhat reassuring, transmasculine patients receiving testosterone may benefit from closer monitoring of lipid profiles.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100349"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000206/pdfft?md5=f4804663c2177e648dc494ba17487bc7&pid=1-s2.0-S2214623724000206-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140822915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)","authors":"Mariam M. Ali ,&nbsp;Sanober Parveen ,&nbsp;Vanessa Williams ,&nbsp;Robert Dons ,&nbsp;Gabriel I. Uwaifo","doi":"10.1016/j.jcte.2024.100341","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100341","url":null,"abstract":"<div><p>Obesity and chronic kidney disease are two ongoing progressive clinical pandemics of major public health and clinical care significance. Because of their growing prevalence, chronic indolent course and consequent complications both these conditions place significant burden on the health care delivery system especially in developed countries like the United States. Beyond the chance coexistence of both of these conditions in the same patient based on high prevalence it is now apparent that obesity is associated with and likely has a direct causal role in the onset, progression and severity of chronic kidney disease. The causes and underlying pathophysiology of this are myriad, complicated and multi-faceted. In this review, continuing the theme of this special edition of the journal on “ The Cross roads between Endocrinology and Nephrology” we review the epidemiology of obesity related chronic kidney disease (ORCKD), and its various underlying causes and pathophysiology. In addition, we delve into the consequent comorbidities and complications associated with ORCKD with particular emphasis on the cardio metabolic consequences and then review the current body of evidence for available strategies for chronic kidney disease modulation in ORCKD as well as the potential unique role of weight reduction and management strategies in its improvement and risk reduction.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100341"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000127/pdfft?md5=345c302048320bbf6f70bf009bc0e8a0&pid=1-s2.0-S2214623724000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine care coordination and visit frequency in pediatric patients with type 1 diabetes in Oregon","authors":"Emily S. Mitchell ,&nbsp;Sarah Andrea ,&nbsp;Ines Guttmann-Bauman","doi":"10.1016/j.jcte.2024.100338","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100338","url":null,"abstract":"<div><h3>Introduction</h3><p>Children with type 1 diabetes require close monitoring with visits every 3–4 months. COVID-19-induced telemedicine expansion may alleviate the challenge of high visit frequency that children with type 1 diabetes face. However, telemedicine’s impact on access to care may be limited if patients lack adequate support for telemedicine. The purpose of this study was to evaluate the impact of telemedicine care coordination services on visit frequency in an urban medical center without care coordination services versus a rural outreach program with established care coordination services serviced by the same providers.</p></div><div><h3>Methods</h3><p>We evaluated EHR data from 790 children receiving care between July 2018 and December 2021 at a single academic center in Oregon. We estimated differences in likelihood of adequately timed monitoring care over time by patient care coordination services status using Generalized Estimating Equations.</p></div><div><h3>Results</h3><p>Just prior to telemedicine expansion, patients receiving care coordination services were 25.6 % less likely to receive adequately timed monitoring care (95 % CI: 51.6 %, 114 %). Following telemedicine expansion, likelihood of adequately timed monitoring care increased from 28.8 % to 58.2 % among those receiving care coordination services and decreased from 38.7 % to 22.0 % among those not receiving care coordination services; increases in adequately timed monitoring care were 3.55 times greater in patients receiving care coordination services relative to those not (95 % CI: 2.10, 6.01).</p></div><div><h3>Discussion</h3><p>For pediatric patients with type 1 diabetes, telemedicine care coordination may be an important factor for increasing visit adherence and may increase the number of patients meeting goal visit frequency beyond levels seen prior to widespread telemedicine availability.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100338"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000097/pdfft?md5=fd6657c5e0847b78cefe19ec67e4f8dd&pid=1-s2.0-S2214623724000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 impacts and inequities among underserved communities with diabetes","authors":"Jennifer L. Maizel ,&nbsp;Michael J. Haller ,&nbsp;David M. Maahs ,&nbsp;Ananta Addala ,&nbsp;Rayhan A. Lal ,&nbsp;Stephanie L. Filipp ,&nbsp;Matthew J. Gurka ,&nbsp;Sarah Westen ,&nbsp;Brittney N. Dixon ,&nbsp;Lauren Figg ,&nbsp;Melanie Hechavarria ,&nbsp;Keilecia G. Malden ,&nbsp;Ashby F. Walker","doi":"10.1016/j.jcte.2024.100337","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100337","url":null,"abstract":"<div><h3>Background</h3><p>People with diabetes have higher COVID-19 morbidity and mortality. These risks are amplified for underserved communities including racial/ethnic minorities and people with lower socioeconomic status. However, limited research has examined COVID-19 outcomes specifically affecting underserved communities with diabetes.</p></div><div><h3>Methods</h3><p>From November 2021 to July 2022, adults with insulin-requiring diabetes at federally qualified health centers in Florida and California (n = 450) completed surveys examining COVID-19 outcomes and demographics. Surveys assessed COVID-19 severity, vaccination uptake, mask-wearing habits, income changes, and healthcare access changes. Surveys also included the full Coronavirus Anxiety Scale (CAS-19). Descriptive statistics were computed for all outcomes. Between-group comparisons for state and race/ethnicity were evaluated via Chi-Squared, Fisher’s Exact, Cochran-Mantel-Haenszel, One-Way ANOVA, and <em>t</em>-tests. Logistic regression determined factors associated with COVID-19 vaccination uptake. Data were self-reported and analyzed cross-sectionally.</p></div><div><h3>Results</h3><p>Overall, 29.7 % reported contracting COVID-19; of those, 45.3 % sought care or were hospitalized. Most (81.3 %) received ≥ 1 vaccine. Hispanics had the highest vaccination rate (91.1 %); Non-Hispanic Blacks (NHBs) had the lowest (73.9 %; p =.0281). Hispanics had 4.63x greater vaccination odds than Non-Hispanic Whites ([NHWs]; 95 % CI = [1.81, 11.89]). NHWs least often wore masks (18.8 %; p &lt;.001). Participants reported pandemic-related healthcare changes (62 %) and higher costs of diabetes medications (41 %). Income loss was more frequent in Florida (76 %; p &lt;.001). NHBs most frequently reported “severe” income loss (26.4 %; p =.0124). Loss of health insurance was more common among NHBs (13.3 %; p =.0416) and in Florida (9.7 %; p =.039). COVID-19 anxiety was highest among NHBs and Hispanics (IQR = [0.0, 3.0]; p =.0232) and in Florida (IQR = [0.0, 2.0]; p =.0435).</p></div><div><h3>Conclusions</h3><p>Underserved communities with diabetes had high COVID-19 vaccine uptake but experienced significant COVID-19-related physical, psychosocial, and financial impacts. NHBs and those in Florida had worse outcomes than other racial/ethnic groups and those in California. Further research, interventions, and policy changes are needed to promote health equity for this population.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100337"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000085/pdfft?md5=7d5c3260b4a794478b1c86202bdb0908&pid=1-s2.0-S2214623724000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140191970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between protein arginine N-methyltransferase 1 polymorphism and overt diabetic nephropathy: Role of asymmetric dimethylarginine in vascular tone","authors":"Hiroaki Iwasaki","doi":"10.1016/j.jcte.2024.100351","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100351","url":null,"abstract":"<div><h3>Background</h3><p>ω-<em>N</em>^G,<em>N</em>^G-asymmetric dimethylarginine (ADMA) regulates vascular tone and may participate in the pathogenesis of diabetic nephropathy (DN).</p></div><div><h3>Objective</h3><p>To investigate whether single-nucleotide polymorphisms (SNPs) around the protein arginine <em>N</em>-methyltransferase 1 gene (<em>PRMT1</em>) influence ADMA dynamics and DN incidence and severity.</p></div><div><h3>Methods</h3><p>This study utilized a hospital-based database containing 310 Japanese patients with type 2 diabetes mellitus (T2DM). The association of <em>PRMT1</em>-related tagged SNPs with DN stage distribution was examined using a dominant model of minor alleles. <em>PRMT1</em> mRNA, serum ADMA, reactive hyperemia-peripheral arterial tonometry index (RHI), and brachial-ankle pulse wave velocity (baPWV) were compared between the genotype-based subgroups of causal SNP, and correlations between these variables were evaluated.</p></div><div><h3>Results</h3><p>The composition of DN stages significantly differed between the GG and GA + AA subgroups of rs892151 (<em>p</em> = 0.026). In a propensity-matching cohort of rs892151, the GA + AA subgroup had an increased incidence of overt DN (odds ratio 2.92, 95 % confidence interval 1.12–7.62, <em>p</em> = 0.028), along with higher <em>PRMT1</em> mRNA, serum ADMA levels, and baPWV than the GG subgroup (<em>p</em> &lt; 0.001, <em>p</em> = 0.023 and 0.047, respectively). There were correlations between <em>PRMT1</em> mRNA and serum ADMA levels, between serum ADMA levels and RHI, and between baPWV and urinary albumin excretion (<em>r</em> = 0.335, <em>p</em> &lt; 0.001, <em>r</em> = -0.221, <em>p</em> = 0.029, and <em>r</em> = 0.254, <em>p</em> = 0.004, respectively).</p></div><div><h3>Conclusions</h3><p>T2DM patients carrying the <em>PRMT1</em>-related variant rs892151 were susceptible to overt DN. ADMA-mediated endothelial dysfunction and arterial stiffness may be involved in the variant-related pathogenesis of overt DN.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100351"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221462372400022X/pdfft?md5=0298406e225eb2d925a3f714ef9fb050&pid=1-s2.0-S221462372400022X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140948807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone health and fracture prevention after kidney transplantation","authors":"Vishal Jaikaransingh","doi":"10.1016/j.jcte.2024.100345","DOIUrl":"https://doi.org/10.1016/j.jcte.2024.100345","url":null,"abstract":"<div><p>Changes in bone health and strength are common after kidney transplantation and can lead to an increased risk of fracture. This has implications for morbidity, mortality and renal allograft survival. This review will focus on the changes that occur in bone health and fracture risk after kidney transplantation and examine the evidence available to guide diagnostic and therapeutic decisions with the aim of fracture prevention.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"36 ","pages":"Article 100345"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623724000164/pdfft?md5=606c703ed432c8d66e6cd07a3e63220a&pid=1-s2.0-S2214623724000164-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140822877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}